Back to News
Market Impact: 0.2
XORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
XORTX Therapeutics outlined plans to submit a Clinical Trial Application to Health Canada for XORLO (XRx-026), its investigational oxypurinol-based candidate for gout. The article provides no submission timeline or indication that the application has been filed or approved.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
XRTX0.35
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Elon Musk intensifies attack on Ambani over Starlink India launch delay
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Why is T-Mobile stock tumbling today?